Two α-S-linked galactosylceramides carrying ω-phenyl fatty acid chains were efficiently synthesized and were shown to have in vitro stimulatory activity for human natural killer T cells.
Introduction
α-Galactosylceramides (α-GalCers) are a class of immunostimulatory agents that are specifically presented by the antigen-presenting molecule CD1d to T cell receptors (TCR) on the surface of natural killer T (NKT) cells. 1 NKT cells are thus stimulated by the CD1d-glycolipid complex and release a variety of T H 1 and T H 2 cytokines; an event associated with profound biological consequences. 2 Of all α-GalCers, KRN7000 3 is the most thoroughly studied and has been tested as an immunotherapeutic agent against many diseases including cancer, diabetes, malaria and hepatitis B. Unfortunately, the efficacy of KRN7000 has been limited in many cases due to the reciprocal inhibition exhibited by T H 1 and T H 2 cytokines. 4 As such, a great deal of effort has been devoted to the synthesis of KRN7000 analogues in the past decade in the hope of developing novel lead compounds with better cytokine-inducing selectivity and appropriate potency. 5, 6 Time course cytokine release studies in mice have shown that once the NKT cell is activated by KRN7000, IFN-γ cytokine release levels (T H 1 response) peak after 12 hours, while IL-4 levels (T H 2 response) peak within 2 hours.
7 Therefore, the stability of the α-GalCer/CD1d
complex is currently a focus point in the design of potent KRN7000 analogues. Increasing the binding interactions between the glycolipid and CD1d, and therefore increasing the stability of the complex, could result in greater levels of IFN-γ release and consequently promoting and prolonging the T H 1 response. Conversely, a less stable α-GalCer/CD1d complex could shorten NKT stimulation time resulting in a T H 2 biased response. 4 Also, other factors, such as the mode of loading the glycolipid into CD1d and the rate of glycolipid dissociation from CD1d in lysosomes, could greatly influence the cytokine release profile as well. Recent crystallographic analysis has indicated that the lipid chains of α-GalCer are buried in a groove in CD1d containing two hydrophobic pockets (denoted as A' and C') and the galactose ring is exposed for the recognition by NKT TCR. 8 The phytosphingosine chain sits in the hydrophobic C' pocket which ideally accommodates 18 carbons, while the longer acyl chain binds in the other hydrophobic A' pocket that can accommodate up to 26 carbons. In addition, several hydrogen bonds were identified and are assumed to anchor α-GalCer in a distinct orientation and position it in the lipid-binding groove. As such, the modification of the lipid chains of α-GalCer is a very important aspect for designing α-GalCer analogues seeing that the chains are strongly involved in the binding with CD1d. For instance, if the lipid chains could be rationally modified to enhance their hydrophobic interaction with CD1d, as mentioned above, the resultant complex may preferably induce the release of T H 1 cytokines, which are thought to be responsible for the antitumor, antiviral and antibacterial effects of α-GalCer. In this regard, a paper by Wong and co-workers attracted our attention, wherein several α-GalCer analogues with greater anticancer efficacy were reported. 9 They introduced different aromatic groups into the fatty acyl chain with a view to designing tighter CD1d-binding glycolipids since X-ray crystal structures showed that the CD1d A' binding groove was lined with numerous aromatic side-chain residues. These analogues were expected to introduce extra aromatic interactions which could increase the stability of the CD1d/glycolipid complex, thereby favouring the induction of T H 1 cytokines. Indeed, some of these analogues with the appropriate fatty acid acyl chain length were four times more potent than α-GalCer itself and were biased towards IFN-γ secretion. 9, 10 Computational, docking of these analogues in the human CD1d hydrophobic groove was also conducted, and the results indicated that their binding mode did not vary much from the crystal structure of α-GalCer bound to hCD1d. In each case, the phytosphingosine chain was bound to the C' pocket and the A' pocket was occupied by the modified fatty acid acyl chain with the galactose headgroup presented in nearly the same conformation as α-GalCer. Additional beneficial binding forces between the terminal phenyl group and Tyr73 or Trp40 were proposed. 9 Recently, several thioglycoside analogues of KRN7000 have been readily synthesized in a highly stereoselective manner in our laboratory, 11 in which an α-galactosyl thiol was used as the sugar building block. It is well known that thioglycosides often exhibit high stability against chemical and enzymatic hydrolysis, 12 so these analogues were expected to have relatively long lifetimes in a biological setting. Also, thioglycosides usually have more flexibility around the anomeric linkage compared with the corresponding O-glycosides owing to the longer C-S bond and weaker stereoelectronic effects. This increased flexibility may thus enable α-S-GalCer to sit differently than α-O-GalCer in the CD1d binding groove, resulting in an altered structure of the glycolipid/CD1d complex and a change in its affinity with the TCR of NKT cells. In addition, after binding with CD1d, the sugar head of α-S-GalCer may orientate in a different angle from that of α-GalCer as the C-S-C bond angle is significantly smaller than the C-O-C angle, which could result in differential recognition by TCR of NKT cells. The subsequent bioassay demonstrated that the α-S-GalCer possessed similar potency to KRN7000 in human NKT cell activation, and stimulated cytokine release in a similar CD1d-dependent manner as well. 13 Therefore, the thioglycoside analogues may be superior to KRN7000 as a parent compound for developing immunostimulants for humans in view of its bioactivity, stability, ease of synthesis, and flexibility in terms of the preparation of other analogues. Based on this work, we wish to report here the synthesis of two new thioglycoside analogues of α-GalCer, 1 and 2 containing a terminal phenyl group in the fatty acid chain with the long-term aim of developing therapeutic analogues with greater anticancer efficacy.
Results and Discussion
Our synthesis started with the preparation of phytosphingosine precursor 6. The aldehyde 3 was first prepared by a known procedure 14 and subjected to the Grignard reaction with tetradecylmagnesium bromide generated from 1-bromotetradecane and Mg to give the alcohols 4 and 5 in 47% overall yield (Scheme 1). As previously reported, 15 the substrate-induced stereoselectivity favoured the formation of the unwanted isomer 4, and the desired isomer 5 was produced as the minor product with a ratio of 4:5 = 1 Removal of the benzylidene protecting group from 6 was then conducted by treatment with p-TsOH in MeOH-CH 2 Cl 2 to afford 9 16 in 80% yield, which was treated subsequently with NaN 3 under heating to give the azide 10 16 in 74% yield. In this project, another goal was to optimize the previous synthetic route to the thioglycoside analogue of KRN7000 with a view to providing larger amounts of samples in a rapid way for more biological studies. Hence, the direct synthesis of the azide 10 from commercially available phytosphingosine 11 (as its hydrochloride salt) was investigated (Scheme 2). Following the literature procedures, 17 the diazo transfer from triflic azide onto the amine was found to proceed extremely well, and 10 was produced in an excellent yield. A convenient and highly efficient route to the key intermediate 10 was thus established, which expedited the synthesis of α-S-GalCers. Compound 10 was then subjected to standard isopropylidenation conditions (2,2-dimethoxypropane/p-TsOH). 15 Perhaps not unexpectedly, the di-ketal intermediate 12 was formed in a mixture also containing 13 but this mixture could be converted directly into compound 13 without purification. Compound 13 was then mesylated with methanesulfonyl chloride in pyridine to give compound 14 in almost quantitative yield, which was converted into the iodide 15 in a good yield by treatment with LiI in DMF. Subsequently, glycosylation of 15 with the pre-prepared α-galactosyl thiol 16 18 . α-S-Linked galactosylceramides carrying ω-phenyl fatty acid chains display stimulatory activity for human NKT cells. CD1d-transfected HeLa cells were pulsed with medium alone, α-GalCer (0.1 µg/mL), or the thioglycoside analogues α-S-GalCer, respectively, using ELISA. Figure 2 shows that comparable levels of IFN-γ and IL-4 were released by NKT cells stimulated with α-GalCer and α-S-GalCer. Compounds 1 and 2 also induced IFN-γ and IL-4 production but only when used at 100-fold higher concentrations (10 µg/mL) than those of the parent compound that were found to activate NKT cells. Compounds 1 and 2 did not appear to skew NKT cell cytokine production to T H 1 or T H 2. IL-10 was not detected in the supernatants of any of the co-cultures (not shown).
Compounds 1 and 2 were tested alongside KRN7000 (α-GalCer) and its thioglycoside analogue (α-S-GalCer) for their ability to stimulate cytokine production by human NKT cells lines in vitro. Mock-transfected or CD1d-transfected HeLa cells were pulsed for 18-24 hours with medium alone or with 0.1, 1 or 10 µg/mL of glycolipid antigen. 13, 19 Equal numbers of expanded and rested NKT cells were added for a further 24 hours and cell supernatants were then harvested and assayed for the T H 1, T H 2 and regulatory cytokines IFN-γ, IL-4 and IL-10, Compound 1 or Compound 2 at 0.1, 1 and 10 µg/mL (increasing concentrations denoted by triangles). After 24 hours equal numbers of expanded human NKT cells were added. As positive controls, NKT cells were stimulated with phorbol myristate acetate (50 ng/mL) and ionomycin (1 µg/mL) (PMA/I). After a further 24 hours, supernatants were harvested and analysed for IFN-γ (top), IL-4 (bottom) and IL-10 (not shown) production. Data are representative of experiments using 5 NKT cell lines.
Conclusions
In conclusion, in this report two α-S-linked galactosylceramides (1 and 2) were efficiently synthesized based on our previously reported synthetic strategy. The Mitsunobu reaction was utilized to retrieve the unwanted diastereoisomer 4, also formed in the original synthesis of the sphingoid building block, and in doing so the synthetic efficiency was greatly improved. The synthetic route was further optimized by directly converting the commercially available phytosphingosine 10 into the sphingoid building block. The synthetic strategy presented here could also be extended to the synthesis of other thioglycoside analogues of α-GalCer. The bioassays showed that compounds 1 and 2 bind to CD1d and stimulate human NKT cell lines in vitro. The addition of ω-phenyl fatty acid chains to α-S-GalCer rendered these compounds less potent as NKT cell stimulators with up to 100 times more of compound 1 or 2 required to elicit similar cytokine levels as seen for the parent compound. Addition of ω-phenyl fatty acid chains to α-S-GalCer did not result in skewing of T H 1/T H 2 cytokine profiles as demonstrated by measurement of IFN-γ and IL-4 production. This data shows that thioglycoside analogues of α-GalCer have bioactivity for human NKT cells. Because of their ease of synthesis and increased stability in biological systems, these compounds may be superior to their non-thioglycoside counterparts as adjuvants for immunotherapies.
Experimental Section
General. All chemicals used were reagent grade and used as supplied except where noted. Reactions were performed in oven-dried glassware under a nitrogen atmosphere using dry solvents. Solvents were evaporated under reduced pressure while maintaining the water bath temperature at 40 °C. All reactions were monitored by thin-layer chromatography (TLC) using silica gel 60 F 254 coated on aluminium sheets and the compounds visualized by UV, or by treatment with 8% H 2 SO 4 in methanol followed by heating. Flash chromatography was performed with the appropriate solvent system using 40-60 µm silica gel. Optical rotations were measured at 20 °C with a Perkin-Elmer 343 polarimeter (1 dm cell) and are quoted with units of 10 -1 degcm 2 g -1 .
1 H NMR spectra were obtained on a 300 and 400 MHz and reported in parts per million (δ) relative to the response of the solvent, or to TMS (0.00 ppm). Coupling constants (J) are reported in Hertz (Hz). 13 C NMR spectra were recorded at 75 or 100 MHz by using CDCl 3 or C 5 D 5 N as solvent and are reported in δ relative to the response of the solvent and the signals were assigned with the aid of DEPT, HSQC spectra. Yields refer to chromatographically pure compounds and are calculated based on reagents consumed. (8) . Triphenylphosphine (7.5 g, 29 mmol) and p-nitrobenzoic acid (4.7 g, 28 mmol) were mixed in anhydrous THF (66 mL) followed by the addition of DIAD (5.7 mL, 29 mmol). A solution of compound 7 (5.6 g, 12 mmol) in THF (40 mL) was added dropwise to the mixture and the reaction was left to stir overnight at room temperature. The mixture was concentrated in vacuo, and the residue was purified by column chromatography (c-Hex:EtOAc, 8:1→3:1), the collected compound was then flushed through a column of silica with CH 2 Cl 2 to remove remaining impurities to afford 8 (5.5 g, 76%) as a white solid: R f = 0. (18) . A 1M solution of triphenylphosphine in THF (1 mL, 1.0 mmol) was added dropwise to a solution of compound 17 (159 mg, 0.19 mmol) in THF (6 mL) at room temperature. After stirring for 2 h, 1M aqueous NaOH (3 mL) was added and the reaction was left to stir for a further 2 h. The solution was then diluted with EtOAc (15 mL) and washed with water (10 mL) and brine (10 mL 4, 128.35, 128.30, 128.2, 128.15, 127.85, 127.80 127.68, 127.55, 127.4, 126.9, 125.5 9, 31.5, 29.7, 29.65, 29.6, 29.55, 29.53, 29.50, 29.45, 29.36, 29.35, 29.34, 29.33, 29.28, 28.9 (19) . A 1M solution of triphenylphosphine in THF (0.21 mL, 0.21 mmol) was added dropwise to a solution of compound 17 (38 mg, 0.04 mmol) in THF (1.5 mL) at room temperature. After stirring for 2 h, 1M aqueous NaOH (0.6 mL) was added and the reaction was left to stir for a further 2 h. The solution was then diluted with EtOAc (10 mL) and washed with water (5 mL) and brine (5 mL). The organic layers were combined, dried over MgSO 4 and concentrated in vacuo to afford the amine as a colourless oil. A mixture of the crude amine, EDC (15 mg, 0.08 mmol) and ω-phenyldodecanoic acid (14 mg, 0.05 mmol) in dry CH 2 Cl 2 (3 mL) was stirred at room temperature overnight. The mixture was diluted with CH 2 Cl 2 (10 mL) and washed with water (5 mL) and brine (5 mL), the organic layer was dried over MgSO 4 and concentrated in vacuo to give a residue which was purified by column chromatography 7:1) 8, 128.61, 128.60, 128.56, 128.4, 128.11, 128.09, 128.05, 127.9, 127.8, 127.7, 125.8 (12C, Ar) 2, 138.9, 138.40, 138.38 (4C, 4 o C), 128.8, 128.75, 128.70, 128.6, 128.5, 128.3, 128.2, 128.1, 128.0, 127.8, 127.3, 125.9 (12C, Ar), 74.9, 74.0 (2C, CH 2 ), , 73.1 (CH 2 ), 72.8 (C-5′), 63.3 (C-6′), 53.1 (C-2), 37.1 (C-2″), 33.4, 33.2 (2C, CH 2 ), 31.9, 30.07, 30.04, 30.02, 29.97, 29.92, 29.90, 29.87, 29.86, 29.77, 29.72, 29.70, 29.68, 29.61, 26.17, 26.09, 26.08, 26.06, 23.04 (19C, CH 2 3325, 2923 , 2852 , 1646 , 1539 , 1468 , 1462 , 1122 , 1083 , 1034 1 H NMR (400 MHz, CDCl 3 ) δ 7.39-7.24 (m, 18H, Ar), 7.18-7.16 (m, 2H, Ar), 6.38 (d, 1H, J 8.8 Hz, NH), 5.47 (d, 1H, J 5.5 Hz, 4.92 (d, 1H, J 11.8 Hz, CH 2 ), 4.84 (d, 1H, J 11.8 Hz, CH 2 ), 3H, CH 2 ), 4.60 (d, 1H, J 11.6 Hz, CH 2 ), 4.27 (dd, 1H, J 5.4, 9.9 Hz, 2H, 2H, 3.69 (dd, 1H, J 2.7, 10.0 Hz, 2H, 3.50 (dd, 1H, J 3.1, 12.0 Hz, 3.06 (dd, 1H, J 9.4, 14.6 Hz, 2.83 (dd, 1H, J 3.0, 14.7 Hz, 7, 128.63, 128.60, 128.4, 128.2, 128.1, 128.0, 127.8, 127.7, 125.8 (10C, Ar) , 87.5 (C-1′), 79.7 (C-3′), 76.8 (C-3/C-4), 76.6 (C-2′), 75.3 (C-4′), 74.8 (CH 2 ), 73.9 (CH 2 ), 73.1 (C-3/C-4), 73.0 (CH 2 ), 72.7 (C-5′), 63.2 (C-6′), 53.1 (C-2), 37.0 (C-2″), 36.2 (C-12″), 33.3 (CH 2 ), 33.1 (C-1), 32. 2, 31.7, 29.93, 29.89, 29.81, 29.75, 29.6, 29.5, 26.03, 25.96, 22.9 (11C, CH 2 3, 30.7, 30.6, 30.43, 30.41, 30.39, 30.3, 30.26, 30.21, 30.17, 30.15, 30.0, 29.95, 27.0, 26.8, 23.3 (16C, CH 2 
1,3-O-Benzylidene-2-O-methanesulfonyl-4-O-p-nitrobenzoyl-D-arabino-1,2,3,4-octadecanetetrol

3,4-O-Isopropylidene-2-(ω-phenylundecanoylamino)-1-S-(2′,3′,4′-tri-O-benzyl-α-D-galactopyranosyl)-D-ribo-3,4-octadecanediol
3,4-O-Isopropylidene-2-(ω-phenyldodecanoylamino)-1-S-(2′,3′,4′-tri-O-benzyl-α-Dgalactopyranosyl)-D-ribo-octadecanediol
2-(ω-Phenylundecanoylamino)-1-S-(2′,3′,4′-tri-O-benzyl-α-D-galactopyranosyl)-D-ribo-3,4-octadecanediol (20
2-(ω-Phenyldodecanoylamino)-1-S-(2′,3′,4′-tri-O-benzyl-α-D-galactopyranosyl)-D-ribooctadecanediol (21
1-S-(α-D-Galactopyranosyl)-2-(ω-phenyldodecanoylamino)-D-ribo-3,4-octadecanediol (2).
Sodium (23 78.1 (C-3′), 74.0 (C-5′), 72.9 (C-3, C-4), 71.5 (C-4′), 70.6 (C-2′), 63.5 (C-6′), 37.3 (C-12″), 36.6 (C-2″), 34.5, 32.8 (2C, CH 2 ), 32.6 (C-1), 32. 3, 30.8, 30.6, 30.48, 30.46, 30.44, 30.38, 30.31, 30.30, 30.24, 30.20, 30.07, 30.01, 27.1, 26.9, 23.4 (10 5 cells/well) as described previously 13, 19 . α-GalCer and α-S-GalCer were added at concentrations of 0.1 µg/ml, whereas Compounds 1 and 2 were tested at 0.1, 1 and 10 µg/ml. After 24 hours, equal numbers of expanded NKT cells, which were rested by culturing for at least 1 week in the absence of IL-2, were added to the glycolipid-pulsed HeLa transfectant cells. After a further 24 hours, cell supernatants were harvested and assayed for IFN-γ, IL-4 and IL-10 by ELISA (R&D Systems (Abingdon, UK).
